As a result of short-term fetal and maternal safety data, chemotherapy is increasingly used to treat pregnant patients with cancer. As pregnant patients are typically excluded from clinical trials, there is a high unmet medical need for adequate and tolerable dosing regimens in this patient population. By incorporating gestational changes into existing population pharmacokinetic models, it is possible to adequately predict plasma concentrations of drugs in pregnant patients which may inform dose adjustments in this population.